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Abstract 
Orodispersible films (ODF) hold promise as a novel delivery method, with the potential to 
deliver tailored therapies to different patient populations.  Together with the current trends 
and potential therapeutic areas such technology can address, some of the unmet needs in 
terms of quality aspects and manufacturing of conventional and novel (printed) ODF are 
discussed.  Overall, this article aims to stimulate further research to fill the current knowledge 
gap between manufacturing and administration requirements of ODF targeting specific 
patient subpopulations such as geriatrics. 
Keywords: orodispersible film, inkjet printing, acceptability, substrate, disintegration, drop-
on-demand 
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1. ODF: A potential formulation strategy for special patient populations 
There is an increasing need of developing new drug delivery platforms to address the needs 
of special patient populations.  For example, the paediatric patient requires the medicine 
dosage to be adequate to the constantly increasing body weight.  As medicinal products 
containing the required dosage may not be available, the practice of splitting tablets, opening 
capsules, or mixing powders with foods or liquids may lead to dose inaccuracy and other 
consequences for the safety of the patient and the efficacy of the treatment (Visser et al., 
2016).  Similarly, other populations may have specific needs with respect to medicine 
administration (Grimsrud et al., 2015; Slavkova and Breitkreutz, 2015; Stegemann et al., 
2010).  Therefore, the development of drug delivery platforms that can help addressing the 
needs of specific patient populations is greatly needed. 
Orodispersible films have been reported to contribute to an improved patient compliance by 
improving ease of administration and by not requiring water (Bala et al., 2013; Krampe et al., 
2015).  Furthermore, ODFs offer a wide range of features that can be easily adapted to the 
needs of individual patients or patient populations. 
According to Borges and colleagues, patients suffering from dysphagia or subjected to an 
increased risk of chocking can benefit from the employment of ODF platforms for drug 
administration. As ODFs are inherently easy to administer, young and older patients can have 
access to a platform that can ensure a complete and precise dosing of medicines, minimising 
the risk of partial loss of actives due to tablet crushing or imprecise liquid administration.  
Moreover, medicine administration to uncooperative patients can be facilitated by the 
adhesion of ODFs to the oral cavity, therefore preventing the medicine to be spit out.  Other 
ODF features such as flexibility, portability, and stability can confer superiority to other 
dosage forms like orodispersible tablets or liquids (Borges et al., 2015a) (Borges at al., 2015 
vol I).  Delivering actives via ODFs through oral mucosa, can lead to rapid dissolution and 
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fastest onset of action (Ashraf and Sayeed, 2014; Choudhary et al., 2013).  Some examples of 
ODF products are commercially available for Alzheimer’s disease (Donepezil – Labtech, 
Kyukyu Pharmaceuticals, Hexal Pharmaceuticals), emesis (Ondansetron – Monosol, Labtech, 
Aavishkar), schizophrenia (Olanzapine – Labtech, Hexal Pharmaceuticals), migraine 
(Zolmitriptan – Monosol, Labtech, NAL Pharma) etc. (Borges et al., 2015a). The readers are 
referred to a recent review by Borges et al. for a comprehensive product list of oro-mucosal 
film based products that are registered, launched, under (pre-) clinical development or 
withdrawn/ discontinued. 
The acceptability of ODFs was described in a recent paper considering the features of the 
final product including appearance, composition, taste and mouthfeel (Krampe et al., 2015). 
ODFs are considered to be age-appropriate oral  dosage forms mainly with respect to its 
disintegration in the oral cavity upon administration without water.  Furthermore, ODFs offer 
the possibility to implement taste masking technologies in order to minimise the averseness 
of the taste of the Active  Pharmaceutical Ingredient (API).  Mouthfeel and texture are also 
considered key characteristics potentially affecting the acceptability of ODFs, particularly 
with regards to the presence of residual particles following disintegration (Krampe et al., 
2015).  Mouthfeel in the sensory evaluation of foods has been related to the primary role of 
the saliva function.  A reduced salivary production could therefore alter the mouthfeel of a 
product in specific patient groups such as patients under treatment for HIV, or older patients 
subjected to polypharmacy (Gupta et al., 2006; López-Verdín et al., 2013; Stokes et al., 
2013). Other features like appearance, mucosal irritation, and API absorption are also 
considered relevant features to take into consideration when designing an ODF formulation 
(Krampe et al., 2015). 
In addition to the aforementioned ODF characteristics, other features could potentially 
positively or negatively affect the patient acceptability of the dosage form, and should be 
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further explored. As proposed in Figure 1, the handling, placement and disintegration of 
ODFs are key stages to identify the full product features with high potential impact on patient 
experience.  For example, the “stickiness/adhesiveness” of the film potentially contributes to 
placement in the mouth and subsequently the overall mouthfeel of the product. Krampe and 
colleagues have referred to the “gummy” nature of the films after wetting as potentially 
contributing to the mouthfeel of the dosage form (Krampe et al., 2015). Moreover, in the case 
of patients experiencing poor manual dexterity, poor hand sensitivity or reduced pinch 
strength (Stegemann et al., 2016), high ODF stickiness may result in the inability to properly 
handle the dosage form.  These properties are largely related to the intrinsic properties of the 
carrier polymers, eg. hygroscopicity and interfacial attributes. The ODF formulation is 
designed to disintegrate fast once placed in the mouth. Wettability, disintegration, and 
dissolution time of the film may change depending on the saliva production rate of the user. 
These parameters are considered to govern the performance of ODF drug products.  
Therefore, in the case of patients affected by severely impaired saliva production (dry mouth 
syndrome), ODFs may not be the dosage form of choice for drug administration. 
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Figure 1: The potential features of ODF formulation influencing different criteria of films as potential patient 
acceptability factors (Ink formulations in case of printed ODF, described below). 
 
 
  
2. Formulation, process and quality considerations of orodispersible films products 
ODF products are conventionally manufactured via film casting of solution, suspension or 
melt using diverse technologies such as solvent casting, semisolid casting, rolling, coating 
and hot melt sheet extrusion (Borges et al., 2015a; Krampe et al., 2015).  In these cases, the 
API(s) is/are dispersed in a feedstock with the suitable excipients, formulation and/or process 
aids and processed to yield films of desired dimensions and mechanical properties.  
Typically, therefore, ODF formulations have the structure of a matrix-based composite film.  
The current co-matrix formulation and process platforms intrinsically harbour some 
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limitations in terms of content uniformity and the ability to combine and diversify doses 
because the final formulation is homogeneous. Furthermore, due to their moderate size and 
thickness ODFs can typically be loaded only with limited drug concentrations per unit 
volume and surface area (Bala et al., 2013).  Therefore, oral films are not generally suitable 
for treatments requiring high dosages, although up to 50% drug loading in an ODF (Gas-X 
Strips®, Novartis) has been reported (Siddiqui et al., 2010). 
The ODF design process should take several parameters into consideration: therapeutic 
target, patient population, safety, appropriateness and compatibility of API and excipients, 
processability of the polymeric mixture, impact on stability, physicochemical and mechanical 
characteristics of the final product, residual solvent/water content, drug release profile, 
packaging, and acceptability to the end user.  Each pharmaceutical development stage can 
have a deep impact on the quality of the final product and must be carefully evaluated. 
2.1 Manufacturing technologies 
The most widespread technologies for ODF manufacture include solvent casting and semi-
solid casting as broadly described by Hoffmann and colleagues (Hoffmann et al., 2011a). 
These generally include feed stock of drug-excipient solution or suspension in aqueous 
and/or non-aqueous media. The use of organic solvents in solvent casting can improve the 
solubility of some APIs.  Conversely, residual amounts of solvents could remain in the final 
product.  Other manufacturing parameters, such as casting solution homogeneity, stability 
and film thickness, must be accurately monitored to ensure a smooth process. 
Hot melt extrusion (HME) offers the advantage of a solvent-free process for ODF 
manufacturing (Palem et al., 2016, 2013; Park et al., 2015; Repka et al., 2003).  Yet, poor 
availability of suitable polymers and high temperatures may pose stability issues to the active 
(Hoffmann et al.,  2011).  HME is a continuous manufacturing process. The scaling up/ down 
for ODF manufacturing via hot melt sheet/film extrusion can depend upon the capacity of 
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downstream shaping process.  Other recently developed technologies offer alternatives to 
ODF manufacturing.  Electrospinning of drug-loaded polymeric solutions has increased in 
popularity in the pharmaceutical area.  This technology allows an increase in drug solubility 
and produces fast dissolving polymeric films in a cost-effective way.  Recently, drug loaded 
electrospun fast dissolving nanofibers have been manufactured and characterised 
(Illangakoon et al., 2014).  The key challenges for electrospun fibers are their poor 
mechanical characteristics and poor handling characteristics that can impede downstream 
manufacturing (filling, flow, packaging) as well as intake by patient. 
Establishment of dedicated facilities for development and commercial scale production of 
personalised ODFs requires many techno-economic considerations (Rantanen and Khinast, 
2015; Tucker et al., 2016).  Some of them are: i) availability of manufacturing technologies 
and status of in terms of readiness for the industrialisation, ii) types of equipment, scale and 
cleaning/maintenance and possibility of scale up and scale down, iii) (critical) process 
parameters, process integration, control and monitoring, iv) batch versus continuous 
operations, v) throughput/capacity and vi) packaging.  The variation in formulations (eg. 
water content of the feed, viscosity, melt temperature) is the one of the key determinants of 
cooling/ drying time and therefore the entire process efficiency.  On the other hand, the 
required size of the strip varies with the (personalised) dose, which can complicate primary 
packaging (eg. different pouch sizes and sealing times). 
2.2 General formulation principles 
The basic structure of oral films is a polymeric matrix.  Typical polymeric carriers used in 
ODF manufacturing include cellulose, starches, gums and polysaccharides, proteins, and 
semi-synthetic or synthetic pharmaceutical grade polymers (Borges et al., 2015b).  Carrier 
polymer selection prerequisites for ODF formulations include solubility in water and/or 
diverse processing solvents, film forming properties, compatibility with wide range of APIs, 
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safety and availability of different molecular weights/ degrees of substitution (Moritz, 2006). 
Depending on the physical and chemical properties of polymers or mixtures of polymers and 
the quality target product profile, the processability can be either favoured or impeded.  For 
example, highly viscous polymer mixtures in melt extrusion lead to difficulty in processing.  
In this respect, it is common practice to incorporate some plasticisers in the formulation. In 
addition surfactants are used to enhance solubility of poorly soluble drugs as well as the 
wettabilityof ODFs (Hoffmann et al., 2011a). 
Some small fractions of other functional excipients such as humectants and/or saliva 
stimulating agents, sweeteners, oro-mucosal permeation enhancers and trace 
colouring/flavouring agents are used (Hoffmann et al., 2011a).  The impact of each 
component to the final product should be evaluated during development. Therefore, the 
selection of film forming polymers should result in a balanced choice ensuring good 
processability yet possessing the desired film characteristics, most importantly in terms of in 
vitro and in vivo pharmaceutical performance and stability.  
2.3 Quality aspects of the final product 
In the absence of regulatory guidelines and due to the novelty of the dosage form, typical film 
potential Critical Quality Attributes (pCQA) have been described in recent publications 
(Borges et al., 2015a; Irfan et al., 2015).  Oral films should have appropriate mechanical 
strength to endure both the stress of the manufacturing pipeline, and folding during post-
production, while maintaining the targeted disintegration and drug release profile.  
Mechanical characterisation studies should include measurement of thickness, tensile 
strength, elongation at break, tear resistance, folding endurance, and Young’s modulus (Irfan 
et al., 2015).  Stability during all manufacturing stages must be carefully studied beforehand 
and monitored throughout.  Particular attention should be paid to unintended or uncontrolled 
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chemical reactions between active and excipients, physical property modifications due to 
high temperatures, and interactions between films and packaging material. 
The drug release profile is another fundamental quality aspect for all types of orally 
administered films.  How fast the film disintegrates, and the rate at which the drug is being 
released classifies the type of film being produced.  With respect to disintegration and 
dissolution characterisation, a range of different dissolution/disintegration testing is available, 
although there is currently no harmonised approach towards the utilisation of a standard 
methodology.  Due to the lack of specific guidelines, USP 1 or 2 dissolution apparatus is 
currently used as standard assays, although several criticisms have been made to the high 
volumes of dissolution/disintegration media employed (Garsuch and Breitkreutz, 2010).  
Film disintegration and dissolution largely depend on the film-forming polymer being used as 
well as the physicochemical properties of API.  The residual water remaining at the end of 
the manufacturing process can significantly affect the mechanical properties, tackiness, 
adhesion properties and stability of the final product.  Humidity of the manufacturing site 
should therefore be controlled and appropriate packaging provided.  The organoleptic 
properties of films are mainly evaluated based on their taste.  Specific flavours and taste 
masking technologies can be used to target different patient populations.  Finally, dose 
uniformity, batch uniformity, homogeneity, impurity profile are likely to be some of the most 
challenging aspects to control. In addition, the physical form of the active and excipients 
(polymorphic form, amorphicity, hydrate/solvate) and phase homogeneity (miscibility, 
molecular mobility etc.) are crucial in terms of drug release characteristics as well as physical 
and chemical stability, therefore should be duly considered. Finally, microbiological 
characterisation can be a quality requirement of ODFs as most of these films are prepared 
from aqueous feed and nutritional carbohydrate or cellulosic polymers. 
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The development of in-line Process Analytical Technology (PAT) tools adaptable for 
monitoring and control of technologies for personalised/individualised drug product (ODF) 
manufacturing is one of the growing areas of interest for both industry and academia.  Zhang 
and colleagues recently demonstrated the implementation of Raman spectroscopy as the in 
line and off line tool for quantification of poorly soluble drugs in strip films (Zhang et al., 
2014). 
 
3. Inkjet printing as an emerging population centric ODF product manufacturing 
platform 
3.1 General overview 
Population-based manufacturing platforms should provide dose flexibility and allow for fixed 
dose combinations to adjust to physiological condition, co-morbidity and altered 
pharmacokinetics  and pharmacodynamics . The conventional cast films offer dose 
stratification mainly based on the cut-strip size, thickness (Krampe et al., 2015), and weight-
strip size.  This complicates possible cross- or downstream processes as well as primary 
packaging.  Two dimensional printing of liquid API or formulation (as inks) to solidify in 
and/or on to ODF as substrate holds considerable potential in flexible dose manufacturing 
with minimal process-steps. Furthermore, InkJet-printed-ODFs (IJ-ODFs) could provide dose 
flexibility  through the adjustment the volume of liquid API deposited onto a fixed-size 
substrate rather than adjusting the size of the film via cutting into different sizes as for 
conventional cast films. Furthermore, homogeneity of drug distribution in cast-films for low 
dose and/or poorly soluble actives is intrinsically challenging.  In this respect, inkjet printing 
technology onto and/or into ODFs has been considered in recent years as a flexible 
manufacturing opportunity for personalised ODF manufacture (Cheow et al., 2015; Genina et 
al., 2013b; Sandler et al., 2011; Vakili et al., 2015).  Current studies are being conducted on 
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the application of the inkjet printing technology to produce dose-flexible oral films (Alomari 
et al., 2014).  A wide diversity of finished solid oral dosage forms such as tablets, hard/soft 
gelation capsules can act as the substrate for printing (Boehm et al., 2015, 2014).  For 
example, the surrogate technology of dispensing drug solutions or suspensions into placebo 
tablets was developed and readied for commercial manufacturing by GlaxoSmithKline 
(GSK) for highly potent actives (Clarke et al., 2012).  Since ODFs are the topic of this article, 
discussion in this direction has been excluded. 
Precise and accurate dispensing of very small doses (pico to micro liter) is achievable by 
printing technology. Small volumes of drugs in liquid can be dispensed on-demand onto the 
film surface to ensure a precise therapeutic drug dose to be delivered to the patient. Inkjet 
printing technologies, resolution/ accuracy, scale, throughput, speed etc. have significantly 
evolved over the last decade (Derby, 2010; Sowade et al., 2016). 
Inkjet printing technology could be also used for pharmaceutical printing of multiple drugs 
onto a single substrate, ensuring drug compatibility, dose precision, and multiple medication-
related issues (Preis et al., 2015). The therapeutic areas where inkjet-printed orodispersible 
film (IJ-ODFs) can potentially improve the ease of administration include pathologies where 
the patient experiences difficulty in self-medicating (severe psychological and neurological 
disorders), and/or difficulty in swallowing (severe neurodegenerative disorders causing 
swallowing difficulties). Therefore, uncooperative/ cognitively impaired, and dysphagic 
patients are major populations that can benefit from rapidly dissolving IJ-ODFs (Abdelbary 
et al., 2014). Furthermore, fast drug-releasing IJ-ODFs design can be further explored for 
managing emergency conditions that require rapid onset of action of the administered drug 
(Karki et al., 2016), such as anaphylactic shock, congestive heart failure and sudden epileptic 
seizure, breakthrough pain and so on  (Alayoubi et al., 2016).  The superiority of the drug 
release performance and medication efficiency of IJ-ODFs against traditional (pre) drug-
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loaded ODF is subject to further verification.  IJ-ODFs, currently under development, can 
better address conditions requiring high dosage precision (Peck, 2015), fixed dose 
combinations (FDC), by printing physicochemically interacting actives and excipients 
spatially as separate drops, and low dosage treatments (Bala et al., 2013; Preis et al., 2015).  
Regulation of drop size, printing pattern and density, etc. can modify the concentration of 
drug printed on a single film with a very high precision (Singh et al., 2010). Further, the 
opportunity of printing specific patterns could serve as a useful form of identification of the 
specific medicinal preparation, especially for patients subjected to polypharmacy (Preis et al., 
2015). The technology is still in a developing phase and readying towards compliance to the 
Good Manufacturing Practice (GMP) requirements for commercial-scale personalised 
pharmaceutical dosage manufacturing (Nallan et al., 2014). More precisely, selection of 
printer material compatible with printing ink, development of cleaning and process validation 
protocols are important issues to be addressed.  Similarly to the more recent 3D printing 
technology (Ventola, 2014), the Inkjet printing platform could find applicability in the 
pharmacy setting.  A personalised orodispersible film can be printed on-site by the 
pharmacist in order to respond to the needs of the individual patient  (Alomari et al., 2014; 
Lind et al., 2016).  For instance, the required therapeutic dose can be adjusted on-site in 
particular benefitting paediatric patients. 
3.2 Inkjet printing on ODFs: A case study 
An exciting advancement in developing understanding of actives printed onto ODFs to 
produce personalised dosage forms has been described in a recent publication (Planchette et 
al., 2015). A non-contact printing system that incorporates complementary inkjet 
technologies (piezoelectric actuator or solenoid valve) was utilised (Figure 2).  Based on this 
approach, a wide range of inks including solutions of physicochemically diverse APIs, 
polymeric nano-suspensions and excipient coating solutions were successfully printed.  The 
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printing process of these diverse inks onto different types of commercial oral ODF placebos 
and customised films were optimised to avoid substrate damage (defects, holes, tears). 
Morphological analysis of the printed surface clearly showed dependence on the ODF type 
used (Figure 3).  A consistent dispensing of drugs with a volumetric deviation of less than ± 2 
% has also been achieved.  
 
Figure 2: Non-contact Printing System SciFLEXARRAYER S3 (Scienion AG, Berlin, Germany) 
incorporating two complementary ink jet technologies. 
 
Figure 3: An overview of inkjet printing of sodium picosulfate solution on different ODF substrate. (A) Plot of 
drop volume measured by drop watcher (♦) and that calculated based on HPLC analysis (solid line) with the 
picture of dispensing unit (inset) and (B) SEM images of printed droplet on to (a) Rapidfilm®, (b) hydrophobic 
non-porous film and (c) hydrophilic porous film. Reprinted (adapted) with permission from (Planchette et al., 
2015) Copyright (2015) Elsevier. 
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3.3 Inkjet printing for personalised ODF manufacturing: unmet needs 
Inkjet printing technology definitely requires further scientific efforts before the 
pharmaceutical drug delivery community embraces personalised dosage manufacturing. 
Engineering solutions to allow the diverse range of benchtop printers, currently used in 
research and development (R&D) applications, up to GMP compliant industrial scale 
processing is the biggest challenge to successful pharmaceutical implementation. 
Formulation aids (e.g. surfactants, crystallisation inhibitors, preservatives etc.) and process 
aids (e.g. viscosity modifiers, co-solvents etc.) can improve the specific printability 
parameters of drug-containing ink solutions such as surface tension and viscosity as well as 
final properties of the printed dosage forms (drug distribution and stability) (Di Risio and 
Yan, 2007; Genina et al., 2012; Wickström et al., 2015).  For sufficient loading of poorly 
soluble drugs, the ink formulations needs to be modified accordingly (non-aqueous solutions, 
nano-suspensions, lipidic formulations) (Williams et al., 2013).  Nucleation and crystal 
growth, Ostwald ripening in supersaturated solutions/ suspensions of poorly soluble drug can 
commence during feeding or during dispensing (nozzle tips).  Inkjet printing using excipient 
stabilised aqueous nano-crystalline APIs as an ink and ODF as a substrate is currently sought 
after as a viable alternative to fabricate individualised dosage form of poorly soluble drug 
(Cheow et al., 2015; Hilgert et al., 2014). 
Beyond ink formulation, various inkjet printing related factors such as satellite drops, nozzle 
clogging, fast evaporation of volatile solvents, coffee ring effect have been an ongoing 
academic and industry R&D topic (Deegan et al., 1997; Hoath et al., 2008, 2012; Reis et al., 
2005; Stringer and Derby, 2010).  For example, an empirical effort to validate the regime of 
fluid “jettability” has been described by Kuang and colleagues in 2014 (Nallan et al., 2014).  
Now, the challenge is to translate this fundamental understanding towards advancing IJ-ODF 
platforms.  Figure 4 illustrates potential ink formulation parameters and printing process 
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parameters that can be critical in obtaining the desired quality attributes of the printed ODF 
dosage forms. 
 
Figure 4: Technical issues involved in various stages of the inkjet printing process and associated parameters 
amenable for process/ product optimisation. 
3.4 Importance of ODF substrate for inkjet printing 
Following the optimisation of ink formulation and printing process, the substrate properties 
are of utmost importance to meet the requirements for desirable product properties (Daly et 
al., 2015).  ODFs as a printing substrate should be developed with consideration given to 
incompatibilities with the potential ink components (drug, solvent, additives) (Genina et al., 
2013; Preis et al., 2015; Raijada et al., 2013).  Poorly soluble drugs are normally challenging 
to incorporate in a water-soluble substrate without sufficient molecular miscibility and 
interfacial interactions.  Nucleation and crystal growth on thin films are dominated by surface 
mobility with much faster kinetics than in bulk (Soutari et al., 2012). Further studies on 
interfacial crystallisation will give some insight about the best strategy to adopt in order to 
predict and control the post-deposition of API morphology (H.-Y. Hsu et al., 2015).  Along 
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with substrate chemistry, modifying film microstructure (such as porosity, inter-connectivity) 
can be an alternatives to enhance drug loading and confine crystal growth, provided cost-
effectiveness and stability (Genina et al., 2013; Sandler et al., 2011). 
3.5 Product quality control and analysis 
Process monitoring and control in terms of content uniformity and compositional 
homogeneity in the printed dosage forms is one of the key issues to be addressed for IJ-ODF 
development.  Model-based process development that involves real time monitoring of the 
deviations in droplet volume dispensed through printer can aid feedback control of the 
process and the time of printing.  Furthermore, quantification of API in printed dots must 
evolve from nano- to pico-liters drops. Therefore, using classical PAT tools is challenging for 
real time quality control of low dose printed formulations.  Recently, Palo and colleagues 
used Attenuated Total Reflectance-Fourier Transformed Infrared Spectroscopy (ATR-FTIR)  
for quantification of two APIs in the printed dosage form (Palo et al., 2016).  To this end, 
hyperspectral (Near Infrared, Raman, Terahertz spectroscopy, Raman spectroscopy and 
chemical imaging etc.) imaging holds immense potential for developing the analytical 
method for API assay and distribution in ODF films (Vakili et al., 2015b; Edinger et al., 
2017) . Novel analytical tools such as optical coherence tomography and interferometry can 
provide fast and non-invasive analysis of printed layer thickness, surface 
roughness/deformation created via solvent evaporation, the degree of adherence of printed 
drops with the substrate as well as spatial distributions (Sandler et al., 2014).  Newman and 
colleagues recently employed Second Harmonic Generation (SHG) microscopy-guided 
synchrotron powder X-ray diffraction to detect 100 ppm crystalline ritonavir in a 
hydroxypropyl methylcellulose (HPMC) matrix (Newman et al., 2015), while SHG 
microscopy-coupled confocal Raman spectroscopy enabled analysis of trace crystallites of 
paclitaxel in lyophilized Abraxane powder (Schmitt et al., 2015).  Such analyses on printed 
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films probably offer solid-state distribution in printed dots and their homogeneity 
(Chowdhury et al., 2014). 
3.6 Inkjet printing for individualised ODF form: S.W.O.T. analysis 
Upgrading industrial-scale inkjet printing for pharmaceutical ODF manufacturing under a 
strictly regulated environment requires significant development effort and capital investment.  
The aforementioned points and the need for dedicated downstream packaging for printed 
ODFs are considered in a strengths, weaknesses, opportunities and threats (S.W.O.T.) 
benchmark analysis for this platform, as presented in Table 1. 
 
Table 1. S.W.O.T. analysis on inkjet printing for personalised IJ-ODF manufacturing. 
Strengths Weaknesses 
 Capability of precise dosing to deliver micro- to 
nano- scale drug loading 
 Possibility of stratified dosage manufacturing and 
one step production of fixed dose combinations 
(FDCs) 
 Availability of a wide ranges of engineering 
options and stronger technological know-how 
existing in allied areas 
 Flexibility of downstream processing 
 Limiting to low dose therapies due to printing 
volume limitation and substrate drug loading 
capacity 
 Difficulty to achieve drop volume uniformity for 
challenging APIs eg. poorly soluble drugs 
 Unavailability of GMP machines for 
pharmaceutical manufacturing 
 Demand for process monitoring and product 
quality control 
Opportunities Threats 
 Population targeted dosage form manufacturing 
(eg. geriatric, paediatric, rare disease, micro-
nutrients) 
 FDC preparations of physicochemically interacting 
APIs 
 Possibly superior strategy for fast releasing ODF 
intended for emergency medications 
 Substrate engineering to prepare printable ODFs 
 Line extension and life cycle management for 
pharmaceutical companies, agricultures, 
nutraceuticals 
 Maturity of conventional film casting 
 Advancements ongoing in film casting, sheet 
extrusion processes 
 Regulatory impedances and uncertainty on 
application due to unavailability of marketed 
products 
 Advancement of other surrogate fields ongoing for 
individualized drug delivery eg. microfluidics, 
dripping 
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4. Polymeric ODF manufacturing by drop printing of molten ink formulation 
An approach similar to solvent-based (inkjet) printing for molten ink formulations is being 
devolved by Reklaitis and colleagues (Reklaitis, n.d.; Hirshfield et al., 2014) .  Briefly, drop-
on-demand (DoD) printing technology is used to deposit molten formulation drops onto 
edible films.  As an example, a recent case study published by Içten and colleagues is 
discussed (Içten et al., 2015a).  Hot melts of naproxen (NAP) and poly (ethylene glycol) 
(PEG) or Pluronic were deposited with high dosing reproducibility onto HPMC-PEG 400 
films.  The process was developed in a semi-continuous operation mode.  The organic 
solvent, API and polymer mixture was heated above its melting temperature and pumped 
through a DoD positive displacement pump. Temperature regulation was extended to the 
whole system including reservoirs, tubing, and nozzles.  The drops were formed by the 
application of a pressure pulse upstream of the nozzle. In order to monitor the process, a 
camera equipped with motor sensors was able to estimate accurately the drop volume and the 
formation of satellite drops.  After ink deposition, the formulation was assessed for its drug 
dissolution profile, reproducibility of dosage amounts, and physical form of NAP after 
printing. 
The drug remained stable as no degradation peaks were detected.. X-Ray diffraction studies 
of showed that the NAP completely crystallized into the starting polymorphic form after 
deposition irrespective of formulation. The differences in the rate and extent of dissolution 
were associated to the polymeric carrier in two formulations. Drug dosage was consistent 
with the number of drops deposited at a low standard deviation.  The high drop placement 
precision and highly controllable drop volume makes this technology suitable for the 
manufacturing of solid dosage forms for high potency drugs.  The same group has also 
recently published on the process control and automation of DoD and the impact of melt 
solidification temperature, drop size and cooling rates in tailoring the melt-crystallisation 
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tendency and in vitro dissolution behaviour of the melt-printed formulations (H. Hsu et al., 
2015; Içten et al., 2015b, 2014).  Prasad and colleagues recently used an electrostatic API or 
formulation powder deposition approach on to the substrate film followed by subsequent 
coalesce of powder with substrate in infrared oven (Prasad et al., 2015). 
5. Conclusion and future direction 
There is an increasing need for patient-centric formulations tailored for patient populations. 
The drug product design should ensure safety and efficacy as well as patient acceptability and 
usability.  The ODF platform is a promising technology broadening the options for 
developing and manufacturing drug products for distinct patient populations. The existing 
technical manufacturing challenges and the lack of consensus on the empirical definition of 
patient acceptability criteria limit the broader industrial investment on conventional and novel 
ODF technology. Collaborative approach of pharmaceutical industry, regulatory bodies and 
academia is required to pave the way towards optimising the quality attributes of ODFs both 
for industrial manufacturing and patient acceptability.  In this perspective, future studies will 
be needed with the purpose of addressing the technical issues encountered by industrial 
partners and simultaneously match the geriatric-centric acceptability criteria suggested in this 
manuscript. 
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